Trial Profile

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mitomycin (Primary)
Indications Urogenital cancer
Focus Therapeutic Use
Sponsors UroGen Pharma

Most Recent Events

12 May 2025 According to UroGen Pharma media release, company plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 by mid-2025.
10 Mar 2025 According to UroGen Pharma media release, company plans to initiate Phase 3 trial to explore the safety and efficacy of UGN-104, for LG-UTUC in the first half of 2025.
20 Jan 2025 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com